LHLiqun He

Liqun He

*This is an algorithmically generated author record based on publicly available information.

Liqun He has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Di Huang

    Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, No. 528 Zhangheng Road, Shanghai 201203, China

    2 shared publications
  • Fei He

    Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine (14DZ2273200), No. 528 Road Zhangheng, Shanghai 201203, China

    2 shared publications
  • Huiling Wang

    Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine (14DZ2273200), No. 528 Road Zhangheng, Shanghai 201203, China

    2 shared publications
  • Jiandong Gao

    Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Jiaoying Ou

    Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine (14DZ2273200), No. 528 Road Zhangheng, Shanghai 201203, China

    2 shared publications
  • Jing Ji

    Shanghai University of Traditional Chinese Medicine, Shanghai, 200120, China; Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200013, China

    2 shared publications

Latest Publications

  • No. 2 Kangxianling decoction (抗纤灵二号方) protects against renal ischemia/reperfusion injury by hypoxia-inducible factor activation

    by Kena Yu, Liping Zhong, Xiaomeng Lin, Jian Chen, Liqun He, Xudong Cai

    To investigate the effect of No. 2 Kangxianling decoction (抗纤灵二号方,No. 2 KXLD) on renal tubular injury in renal ischemia/reperfusion injury (RIRI) rats and explore the mechanisms. Male Sprague-Dawley rats were divided into sham group, RIRI group, No. 2 KXLD group, and FG-4592 group. Rats were pretreated with No. 2 KXLD (30 g·kg-1·d-1, i.g.) or FG-4592 (10 mg·kg-1·d-1, i.p.) for 7 d and then subjected to renal I/R. Serum creatinine (Scr) and blood urine nitrogen (BUN) were tested after I/R. Periodic acid-Schiff staining and tubular injury biomarkers were measured. Hypoxia-inducible factor (HIF), inflammatory response, and B-cell lymphoma 2/Bcl-2-associated X protein/caspase-9/3 (Bcl-2/Bax/caspase-9/3) signaling were determined. We used human kidney 2 (HK-2) cells in a hypoxia/reoxygenation (H/R) model to verify the study. No. 2 KXLD significantly decreased the levels of Scr by 22.4% and BUN by 19.7% at 48 h after I/R and improved the renal pathological changes in RIRI rats. No. 2 KXLD attenuated the expression of kidney injury molecule-1, neutrophil-gelatinase-associated lipocalin, and tissue inhibitor of metalloproteinase-2 in RIRI rats and H/R-induced HK-2 cells (P < 0.05). Both in vivo and in vitro studies demonstrated that No. 2 KXLD increased hypoxia-inducible factor, erythropoietin, and heme oxygenase 1 levels, suppressed tumor necrosis factor-α and interleukin-6 expressions, and boosted Bcl-2/Bax/caspase-9/3 pathway. No. 2 KXLD might have therapeutic potential on RIRI by inhibiting HIF-mediated inflammation and apoptosis, which provides a theoretical basis for the treatment of patients with renal tubulointerstitial injury.

  • Open Access

    Malignant hypertension induces thrombotic microangiopathy and renal failure: A case report

    by Xi Sun, Chunying Bmed Liu, Yanyun Mm Ren, Liqun He, Youhua Xu

    Rationale: Thrombotic microangiopathies (TMA) caused by malignant hypertension is an acute and critical disease among rare diseases. Although renal biopsy pathology is a golden indicator for diagnosing kidney disease, it cannot distinguish between primary and secondary TMA and requires a comprehensive diagnosis in conjunction with other laboratory tests and medical history. Patient concerns: A 33-year-old young man was hospitalized due to unexplained kidney failure. Diagnosis: A young man was admitted to the hospital with unexplained renal failure with severe heart failure and was diagnosed with TMA by renal biopsy. Further investigation excludes primary TMA and is considered to be due to malignant hypertension. Interventions: Temporary hemodialysis combined with aggressive blood pressure control and the use of angiotensin receptor-neprilysin inhibitor are the primary management approach. Outcomes: Upon discharge, the patient had ceased dialysis and showed significant renal function recovery. After 1 year follow-up period, creatinine levels remained stable at 2.373 mg/dL, while lactate dehydrogenase, B-type natriuretic peptide, and platelet levels all returned to within normal ranges. Lessons: TMA caused by malignant hypertension is rare and similar to the clinical manifestations of TMA caused by Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome, but it is often sudden and critical. Early identification and diagnosis and aggressive antihypertensive therapy, must be given to avoid end-stage renal disease, long-term maintenance of dialysis, and the financial burden of unnecessary plasmapheresis and potential side effects of glucocorticoids.


  • Open Access

    Transcriptomic analysis of the mechanisms of alleviating renal interstitial fibrosis using the traditional Chinese medicine Kangxianling in a rat model

    by Yufeng Jiang, Yaohan Zhu, Timing Zhen, Jie Li, Kaichen Xing, Liqun He, Sibo Zhu

    Renal interstitial fibrosis (RIF) is currently recognized as a crucial mechanism of the pathogenesis of chronic kidney disease (CKD). Kangxianling (KXL, anti-fibrin) is a traditional Chinese medicine that has been proven to significantly reduce the levels of ECM deposition and inhibit renal fibrosis. To characterize the mechanisms and drug targets of KXL, we established a RIF rat model and treated the rats with KXL and losartan. Histological analyses validated the establishment of the RIF model and the treatment effect of KXL. Multiple levels of transcriptomic datasets were generated using lncRNA, mRNA and microRNA sequencing of kidney tissues. Functional annotations and pathway analyses were performed to unravel the therapeutic mechanisms. A multi-level transcriptomic regulatory network was built to illustrate the core factors in fibrosis pathogenesis and therapeutic regulation. KXL and losartan significantly reduced the progression of RIF, and a better therapeutic effect was shown with higher concentrations of KXL. According to the cluster analysis results of the RNA-seq data, the normal control (NC) and high concentration of KXL (HK) treatment groups were the closest in terms of differentially expressed genes. The WNT, TGF-β and MAPK pathways were enriched and dominated the pathogenesis and therapy of RIF. miR-15b, miR-21, and miR-6216 were upregulated and miR-107 was downregulated in the fibrosis model. These small RNAs were shown to play critical roles in the regulation of the above fibrosis-related genes and could be inhibited by KXL treatment. Finally, based on the lncRNA datasets, we constructed a mRNA-lncRNA-miRNA coexpression ceRNA network, which identified key regulatory factors in the pathogenesis of kidney fibrosis and therapeutic mechanisms of KXL. Our work revealed the potential mechanism of the Chinese medicine Kangxianling in inhibiting renal interstitial fibrosis and supported the clinical use of KXL in the treatment of kidney fibrosis.


  • Open Access

    Effect of Kangxianling Decoction on Expression of TGF-β1/Smads and Extracellular Matrix Deposition

    by Jing Ji, Liqun He

    Kangxianling (KXL) decoction is a traditional Chinese herbal formulation which has been used to treat early and midterm chronic renal failure. Renal fibrosis is a common characteristic of progressive chronic kidney diseases (CKD). The formation of renal fibrosis is caused by kidney trauma, infection, and immune response. The pathophysiological mechanism of renal fibrosis was mainly due to increased collagen synthesis in the kidney, decreased degradation, and a large amount of extracellular matrix (ECM) deposition. The purpose of this study was intended to evaluate the effect of Kangxianling decoction on expression of TGF-β1/Smad signaling pathway in renal fibrosis rats. 50 specific pathogen-free Sprague Dawley (SPF SD) rats were randomly divided into five groups: control group, sham group, 5/6 nephrectomy model group, 5/6 nephrectomy model plus KXL decoction (21g /kg) group, and 5/6 nephrectomy model plus Losartan Potassium (LP) (33.3 g/kg) group. The rats were all sacrificed after two months and the left kidney tissue was sampled. HE staining was used to observe the renal pathological changes and the score of kidney damage was made. Masson staining was used to observe the degree of renal fibrosis. Immunohistochemical staining, western blot, and qRT-PCR were used to detect the expression levels of related molecules in TGF-β1/Smad signaling pathway. The results suggested that KXL could lighten renal histopathology damage, downregulate the expression of TGF-β1 (transforming growth factor-β1), Smad2/3, CTGF (connective tissue growth factor), Collagen I, and Collagen III, and upregulate the expression level of Smad7.


  • Open Access

    Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats

    by Yansheng Wu, Yixing Wang, Jiaoying Ou, Qiang Wan, Liqiang Shi, Yingqiao Li, Fei He, Huiling Wang, Liqun He, Jiandong Gao

    Objective. To explore the effect and mechanism of ShiZhiFang on uric acid metabolism. Methods. 40 rats were divided into normal group, model group, ShiZhiFang group, and benzbromarone group. The hyperuricemic rat model was induced by yeast gavage at 15 g/kg and potassium oxonate intraperitoneal injection at 600 mg/kg for two weeks. During the next two weeks, ShiZhiFang group rats were given ShiZhiFang by gavage, and benzbromarone group rats were given benzbromarone by gavage. The serum uric acid, creatinine, blood urea nitrogen, XOD activity, urinary uric acid, urinary β2‐MG, and histopathological changes were observed in the rats of each group after treatment. Results. The hyperuricemic model was established successfully and did not show the increase of serum creatinine and blood urea nitrogen. Compared with the model group, the serum uric acid, serum XOD activity, and urinary β2‐MG were significantly decreased (p < 0.05), and 24 h urinary uric acid excretion was significantly decreased (p < 0.01) in ShiZhiFang group, whereas the two treatment groups were of no statistical significant in above indicators (p > 0.05); renal histopathology showed that the lesions in two treatment groups were reduced compared to the model groups. The gene and protein expression of uric acid anion transporters rOAT1 and rOAT3 in the kidney was significantly higher than that in model group (p < 0.01). Conclusion. The model is suitable for the study of primary hyperuricemia. The mechanisms of ShiZhiFang on uric acid metabolism in hyperuricemic rats may be involved in reducing the activity of serum XOD and promoting the transcription and expression of rOAT1 and rOAT3 in the kidney.


  • Clinical study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for glomerular proteinuria patients: A randomized controlled trial

    by Qin Dai, Pei-Qing Zhang, Xiao-Qin Wang, Li-Fang Nie, Xiao-Jun Fu, Wen Peng, Yi Wang, Jun Li, Yue-Ping Bi, Xiu-Hua Mi, et al.

    To explore the therapeutic effect of Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方, YQSR) in patients with glomerular proteinuria.

  • Open Access

    Moxibustion Alleviates Injury in a Rat Focal Segmental Glomerulosclerosis Model

    by Yi Li, Yuxia Sun, Chunling Zhang, Ke Wang, Peicheng Shen, Di Huang, Wen Ma, Jin Zhang, Lin Li, Liqun He

    Objectives. To evaluate the therapeutic effects of moxibustion at Shenshu (BL‐23) and Geshu (BL‐17) acupoints in a focal segmental glomerulosclerosis (FSGS) model in rats. Methods. A FSGS rat model was established by single nephrectomy and repeated injection of doxorubicin. The FSGS rats were randomly divided into the model group, losartan (positive control) group, Shenshu moxibustion group, and Geshu moxibustion group. Molecular indicators of kidney function and renal pathological changes were monitored. Results. Urinary protein, serum creatinine, urea nitrogen, and serum uric acid were significantly reduced after 12‐week intervention with losartan, Shenshu, or Geshu moxibustion. Renal α‐SMA, FN, and TGF‐β were also decreased, while podocin and nephrin protein and mRNA were increased. The pathological damage in renal tissue was obviously alleviated by all three treatments, which suggests that moxibustion may have similar efficacy to losartan in the treatment of FSGS. Conclusion. Moxibustion alleviates podocyte injury and inhibits renal interstitial fibrosis in the FSGS rat model, thereby minimizing the progression of glomerular sclerosis and improving renal function.


  • Open Access

    Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats

    by Yansheng Wu, Fei He, Yingqiao Li, Huiling Wang, Liqiang Shi, Qiang Wan, Jiaoying Ou, Xiaoying Zhang, Di Huang, Lin Xu, et al.

    Objective. Uric acid (UA) activates the NLRP3‐ASC‐caspase‐1 axis and triggers cascade inflammatory that leads to hyperuricemic nephropathy and hyperuricemia‐induced renal tubular injury. The original study aims to verify the positive effects of the traditional Chinese medicinal formula Shizhifang (SZF) on ameliorating the hyperuricemia, tubular injury, and inflammasome infiltration in the kidneys of hyperuricemic lab rats. Method. Twenty‐eight male Sprague‐Dawley rats were divided into four groups: control group, oxonic acid potassium (OA) model group, OA + SZF group, and OA + Allopurinol group. We evaluated the mediating effects of SZF on renal mitochondrial reactive oxygen species (ROS) and oxidative stress (OS) products, protein expression of NLRP3‐ASC‐caspase‐1 axis, and downstream inflammatory factors IL‐1β and IL‐18 after 7 weeks of animals feeding. Result. SZF alleviated OA‐induced hyperuricemia and inhibited OS in hyperuricemic rats (P < 0.05). SZF effectively suppressed the expression of gene and protein of the NLRP3‐ASC‐caspase‐1 axis through accommodating the ROS‐TXNIP pathway (P < 0.05). Conclusion. Our data suggest that SZF alleviates renal tubular injury and inflammation infiltration by inhibiting NLRP3 inflammasome activation triggered by mitochondrial ROS in the kidneys of hyperuricemic lab rats.


  • Open Access

    CXCL16 regulates cisplatin-induced acute kidney injury

    by Hua Liang, Zhengmao Zhang, Liqun He, Yanlin Wang

    CXCL16 regulates cisplatin-induced acute kidney injury